Moonwalk Biosciences
PrivateLast Round
Series B
Sep 8, 2026
Est. Valuation
$150M
Total Funding Raised
$127M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Moonwalk Biosciences operates in Healthcare & Life Sciences and is based in South San Francisco, California. Its latest recorded funding round was a Series B round in September 2026.
Moonwalk Biosciences is a biotechnology company that develops precision epigenetic therapies by coupling an epigenetic discovery platform with precise engineering to reprogram cells to a healthy state.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Moonwalk Biosciences Comparables
Compare Moonwalk Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Tune Therapeutics | 90% | |
| nChroma Bio | 89% | |
| Epigenic Therapeutics | 88% |
For institutional investors. Book with your work email.
Moonwalk Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Sep 8, 2026 | ||||
| Series A | Jan 4, 2024 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Moonwalk Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Future Ventures | Series B, Series A |
| GV | Series A |
| Khosla Ventures | Series B, Series A |
| YK Bioventures | Series B |
| ARCH Venture Partners | Series B, Series A |
| Alpha Wave Global | Series B, Series A |
| Gaorong Capital | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 8, 2026
$70M round led by YK Bioventures and Alpha Wave Global.
- Jul 25, 2026
Monthly visitors increased 38% MoM, reaching 4.6K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingSep 8, 2026
Moonwalk Biosciences, Inc. aims to develop effective, safe and durable epigenetic medicines across a range of indications using insights into cellular epigenetics.
- hiresSep 8, 2026
Moonwalk Biosciences, Inc. appoints Dr Stephen Djedjos as senior vice president, clinical development, to lead clinical efforts.
- is_developingSep 8, 2026
On Sep 8th '26, Moonwalk Biosciences, Inc. is developing siRNA medicines targeting adipose tissue, with new financing supporting pipeline expansion and its proprietary drug discovery platform.
- is_developingSep 8, 2026
In 2024, California-based Moonwalk Biosciences, Inc. plans to develop a treatment based on gene editing technology licensed from the Broad Institute, backed by Arch Venture Partners and Khosla Ventures.
- is_developingSep 8, 2026
As of Sep '26, Moonwalk Biosciences, Inc. is developing small interfering RNA (siRNA) therapeutics designed to act directly on adipose tissue and target non-incretin biology inside fat cells; its lead candidate, MW101, undergoes IND-enabling studies and enters first-in-human studies in late 2027.
For institutional investors. Book with your work email.
Moonwalk Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Moonwalk Biosciences's valuation, stock price, and market status.
Is Moonwalk Biosciences a public or private company?
Moonwalk Biosciences is a private company.
What is the current stock price of Moonwalk Biosciences?
Moonwalk Biosciences is a private company, so its shares have no public market price. Caplight tracks Moonwalk Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Moonwalk Biosciences worth (valuation)?
Moonwalk Biosciences's valuation is estimated at $150.0M based on funding round data.
Can I buy Moonwalk Biosciences stock?
Moonwalk Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Moonwalk Biosciences's last funding round?
Moonwalk Biosciences's most recent funding round was Series B on September 8, 2026.
Who are the main investors in Moonwalk Biosciences?
Key investors in Moonwalk Biosciences include Future Ventures, YK Bioventures, ARCH Venture Partners, Alpha Wave Global.
Will Moonwalk Biosciences IPO soon?
No public IPO plans have been announced for Moonwalk Biosciences.
How can I track Moonwalk Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in Moonwalk Biosciences's shares on secondary markets.